The Full Answer
A real stem cell is a living, undifferentiated cell capable of self-renewal. For orthopedic use, the relevant cells are mesenchymal stem cells (MSCs), found in meaningful concentration in a patient's own bone marrow and fat tissue — which is what the FDA calls autologous therapy. Products derived from donated umbilical cord, Wharton's jelly, amniotic fluid, or placental tissue come from someone else's tissue, are processed and freeze-dried in ways that destroy cell viability, and are not autologous. Under FDA regulation, using them this way requires an approved Biologics License Application, and none of the commercial products marketed this way have one.
What the Current Evidence Shows
The FDA has enforced this distinction since at least 2019, including an August 2026 warning letter to R3 Medical Companies for marketing unapproved umbilical cord and Wharton's jelly products as stem cell therapy. Independent analyses of commercial cord and amniotic products have consistently found no viable mesenchymal stem cells in them.
Who May Benefit
Anyone evaluating a clinic offering "stem cell" injections for joint pain should ask specifically whether the product is autologous (from their own body) or a commercial allogeneic product, and request the source and FDA regulatory basis for the product used.
When Surgery May Be More Appropriate
Dr. Tortland's Perspective
A clinic telling a patient "these are your stem cells" while injecting a lyophilized commercial cord product is not a different treatment philosophy — it's a factually false statement to someone in pain who has often already exhausted other options. If a clinic can't explain exactly what's in the product being injected and where it came from, that's a disqualifying answer.